Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 5 | 0 | 5 |
| 2000 | 3 | 0 | 3 |
| 2001 | 6 | 1 | 7 |
| 2002 | 4 | 0 | 4 |
| 2003 | 9 | 2 | 11 |
| 2004 | 5 | 1 | 6 |
| 2005 | 4 | 1 | 5 |
| 2006 | 13 | 1 | 14 |
| 2007 | 7 | 0 | 7 |
| 2008 | 9 | 2 | 11 |
| 2009 | 6 | 0 | 6 |
| 2010 | 13 | 0 | 13 |
| 2011 | 5 | 0 | 5 |
| 2012 | 5 | 0 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 8 | 0 | 8 |
| 2020 | 2 | 0 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 7 | 0 | 7 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284.
-
Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. Am J Clin Pathol. 2024 Nov 04; 162(5):492-499.
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.
-
FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb; 87(2):110-122.
-
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Dec; 22(6):102198.
-
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis. Urol Oncol. 2024 Nov; 42(11):361-369.
-
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. Urol Oncol. 2024 Sep; 42(9):291.e13-291.e25.
-
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
-
Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 06; 148:1-6.
-
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel. Clin Genitourin Cancer. 2024 Aug; 22(4):102091.